TABLE 2.
Elucidate drug delivery system of nanoparticles in treatment of various disease.
| Nanoparticles | Drug | Particle size (nm) | Diseases | Experimental model | References |
|---|---|---|---|---|---|
| Chitosan (CS) | Mertansine (MRT), cabazitaxel (CBZ) | 112, 110 | Cancer | Human breast cancer cells (MDA-MB-231, MDA-MB-468, and MCF7) | Pandya et al. (2020) |
| CS | Curcumin (CUR) | 115 | Human lung cancer cells (A549), human colon cancer cells (HCT116) | Almutairi et al. (2020) | |
| CS | Boswellic acid (BA) | 67.5–187.2 | A549 cells | Salanki et al. (2020) | |
| CS | Piperlongumine (PL) | 200 | Human dermal fibroblast cells (hDFB), human prostate cancer cells (PC-3) | Choi et al. (2019) | |
| CS | Adriamycin (ADM) | 86.8–102.5 | Kunming (KM) mice | Kou et al. (2017) | |
| Poly (lactide-co-glycolide) (PLGA) | Ferulic Acid (FA) | 200 | Human lung cancer cells (NCI-H460) | Merlin et al. (2012) | |
| PLGA | Doxorubicin (DOX) | 94 | BDF1mice, Wistar rats, and Chinchilla rabbits | Pereverzeva et al. (2019) | |
| PLGA | Thymoquinone (TQ) | 147.2 | Human melanoma cells (A375) | Ibrahim et al. (2020) | |
| PLGA | Ursolic acid (UA), caffeine (Caf) | 120, 100 | Human colon cancer cells (HT29) | Merlin et al. (2017) | |
| PLGA | Brucine (BRU) | 94–253 | MDA tumor bearing mice | Elsewedy et al. (2020) | |
| PLGA | Paclitaxel (PTX) | 127.3 | Nude mice | Duan et al. (2019) | |
| Cellosaurus cell (LO2), MDA-MB-23 cells | |||||
| PLGA | R-flurbiprofen (FLUR) | 150–190 | Wistar rats, rat glioma 2 cells (RG2) | Caban-Toktas et al. (2020) | |
| Poly-lactic acid (PLA) | Docetaxel (DTX) | 100 | ALB/c nude mice, human liver cancer cells (Hep-G2) | Zhu et al. (2016) | |
| Gold (Au) | DTX | 75.90 | BALB/c nude | Gotov et al. (2018) | |
| Mice, human cervical cancer cells (HeLa), MCF-7 cells | |||||
| Au | DOX | 22 | Balb/c mice | Elbialy et al. (2015) | |
| Au | Dichloro (1,2-diaminocyclohexane)platinum (II) (DACHPt) | 183 | BALB/c nude mice | Lee and Shieh, (2020) | |
| Au | Salinomycin (Sal) | 18 | MCF-7 cells | Zhao et al. (2019) | |
| Silver (Ag) | Imatinib (imab) | 105–210 | MCF-7 cells | Shandiz et al. (2017) | |
| Ag | Indocyanine green (ICG) | 100 | Athymic nude mice, murine melanoma cells (B16F10) | Park et al. (2020) | |
| Physalis mottle virus (PhMV) | Cisplatin | 30 | NCr nude mice, MDA-MB-231 cells | Hu and Steinmetz, (2020) | |
| PLGA | Insulin | 297.8 | Diabetes mellitus | Sprague Dawley (SD) rats | Abdelkader et al. (2018) |
| PLGA | Cinaciguat (CCG) | 80 | Rat-derived mesangial cells (rMCs) | Fleischmann et al. (2021) | |
| PLGA | Quercetin (Qu) | 179.9 | SD rats | Chitkara et al. (2012) | |
| PLGA | γ-oryzanol | 214.8 | ob/ob mice | Kozuka et al. (2017) | |
| PLA | Lutein | 152.38 | Wistar albino rats | Mishra et al. (2015) | |
| Mannosylated sodium alginate (MAN-ALG) | Ins29−23 (peptide) | 200–300 | NOD/ShiLtJNju mice | Qu et al. (2021) | |
| Mesoporous silica (mSiO2) | Cerium (III) chloride (CeCl3) | 87.6 | Wistar rats | (Yang et al., 2017) | |
| Ag | Nimesulide (NIM) | 64.25 | SD rats | (Wang Y et al., 2021) | |
| CS | FA | 119.5 | Wistar albino rats | Panwar et al. (2018) | |
| CS | CUR | 50 | Hyperglycaemic rats | Akolade et al. (2017) | |
| CS | Qu | 91.58 | Wistar rats | Mukhopadhyay et al. (2018) | |
| Solid lipid (SLNs) | Resveratrol (RES) | 248 | Wistar rats | Mohseni et al. (2019) | |
| SLNs | Berberine (BBR) | 76.8 | SD rats | Xue et al. (2013) | |
| SLNs | Myricitrin | 50–100 | NMRI mice | Ahangarpour et al. (2018) | |
| Liposomes | Betanin | 40.06 | Wistar rats | Amjadi et al. (2019) | |
| Phytosomes | BBR | 165.2 | Wistar rats, human intestinal epithelial cells (Caco-2) | (Yu F et al., 2016) | |
| Nanocrystals | CUR | 32 | Albino rats | Gouda et al. (2019) | |
| Nanosuspensions | UA | 246.4 | Albino Wistar rats | Singh et al. (2019) | |
| Nanosuspensions | BBR | 73.1 | C57BL/6 mice | Wang et al. (2015) | |
| Nanosuspensions | Betulin | 110 | SD rats | Zhao et al. (2014) | |
| PLGA | Wogonin (Wog) | 194.82 | Cardiovascular | Albino Wistar rats | Bei et al. (2020) |
| PLGA | Vascular endothelial growth factor (VEGF) | 113 | NOD/SCID mice | Oduk et al. (2018) | |
| PLGA | Insulin-like growth factor (IGF1) | 75 | FVB mice | Chang et al. (2013) | |
| PLGA | Cyclosporine A (CsA) | 100 | C57BL/6J, Cyclophilin D−/− mice | Ikeda et al. (2016) | |
| PLGA | Irbesartan | 200 | C57BL/6J, CCR2−/− mice | Nakano et al. (2016) | |
| PLGA | Pitavastatin | 160 | SD rats | Nagaoka et al. (2015) | |
| PLGA | Pitavastatin | 160 | C57BL/6J mice | Mao et al. (2017) | |
| PLA | CUR | 96.67 | Wistar rats | Li et al. (2021) | |
| SLNs | Daidzein | 126 | SD rats, Beagle dogs | Gao et al. (2008) | |
| SLNs | Candesartan cilexetil (CC) | 180–220 | Wistar rats | Dudhipala and Veerabrahma, (2016) | |
| Dendrimer | microRNA-1 inhibitor | 50 | C57BL/6J mice | Xue et al. (2018) | |
| Liposomes | None | 101.5 | Swiss mice | Paulis et al. (2012) | |
| Silicon | siRNA, CCR2, MSCs | 100–200 | BALB/c male mice | Lu et al. (2015) | |
| Polyketal (PK3) | Nox2-siRNA | 500 | C57BL/6J mice | Somasuntharam et al. (2013) | |
| PK3 | Nox2-siRNA | 500 | C57BL/6J mice | (Yang et al., 2017) | |
| Micelles | Nitroxyl radical | 40 | Dog, I/R | Asanuma et al. (2017) | |
| Micelles | CCR2 inhibitor | 34.7 | C57BL/6J mice | (Wang et al., 2018) | |
| Lipid | Cyclosporine A (CsA) | 160 | Chinese Bama swine | Yin et al. (2014) | |
| Lipid | Puerarin | 110 | Wistar rats | Dong et al. (2017) | |
| Lipid | Schisandrin B (Sch B) | 130 | SD rats | Shao et al. (2017) | |
| Iron oxide microrods (MRs) | Tissue plasminogen activator (tPA) | 15 | Neurogenetic | CD1-IGS mouse | Hu et al. (2018) |
| PLGA | Estradiol | 138.8 | SD rats | Mittal et al. (2011) | |
| PLGA | Donepezil | 89.63 | Wistar rats | Md et al. (2014) | |
| PLGA | Rotigotine | 70,000 | SD rats | Wang et al. (2012) | |
| PLGA | Antioxidants | 250–270 | SD rats | Petro et al. (2016) | |
| PLGA | Trimethylated chitosan (TMC) | 136.8 | APP/PS1 double transgenic mice | Wang et al. (2010) | |
| PLGA | Temozolomide (TMZ) | 125.1 | SD rats | Chu et al. (2018) | |
| PLGA | Ropinirole (RP) | 100–120 | Wistar rats | Negro et al. (2017) | |
| CS | Galantamine hydrobromide | 48.3–68.3 | Wistar rats | Hanafy et al. (2016) | |
| CS | Selegiline | 165–255 | SD rats | Sridhar et al. (2018) | |
| CS | Polyamidoamine (PAMAM) | 197 | Wistar rats | Sharma et al. (2018) | |
| CS | Levodopa | Unknown | SD rats | Cao et al. (2016) | |
| CS | Selenium (Se) | 33.11 | Wistar rats | Asl et al. (2021) | |
| Au | Glutathione (GS) | 2.5–3.3 | Kidney | UUO mice | (Yu et al., 2016) |
| Iron oxide (IO) | Gadolinium (Gd) | 4.8 | BALB/c mice | Zhou et al. (2013) | |
| Carbon dot (C-dot) | Infrared dye (ZW800) | 3 | Nude mice | Huang et al. (2013) | |
| Palladium (Pd II) | Poly (vinylpyrrolidone) (PVP) | 4.4 | BALB/c mice | Tang et al. (2014) | |
| Copper (Cu) | GS | 2 | BALB/c mice | Yang et al. (2015) | |
| Silica (Si) | Anti-CD11b | 100 | UUO mice | Shirai et al. (2012) | |
| Au | Methoxy-PEG-thio | 10 | BALB/c mice | Choi et al. (2011) | |
| Gadolinium (AGuIX) | Rhodamine B | 3 | BALB/c mice | Sancey et al. (2015) | |
| Carboxymethyl dextran, PAMAM G5 dendrimer | None | 5 | C57BL/6J mice | Nair et al. (2015) | |
| PLGA | Polyethylene glycol (PEG) | 400 | SKH-1 Elite hairless mice | Williams et al. (2015) | |
| Carbon nanotubes (CNTs) | siRNA | 5 | BALB/c mice | Alidori, et al. (2016) | |
| Liposomes | Anti-E-selectin antibody (AbEsel) | 121 | C57BL/6J mice | Asgeirsdottir et al. (2008) | |
| Collagen IV | Anti-inflammatory peptide (Ac2-26) | 77.15 | C57BL/6J mice | Kamaly et al. (2013) | |
| Polycation (CDP/AD-PEG) | siRNA | 60–100 | BALB/c mice | Zuckerman et al. (2012) | |
| Albumin | Celastrol | 75 | SD rats | Guo et al. (2017) | |
| Poly (ethylene glycol)-poly (l-lysine) (PEG-PLL) | siRNA | 10 | MRL/lpr mice | Shimizu et al. (2010) | |
| Lysozyme | Sunitinib analog (17,864) | Unknown | C57BL/6J mice | Dolman et al. (2012) | |
| Captopril (CAP) | G3-C12 (GSG) | 215 | Kunming strain mice | Geng et al. (2012) | |
| CS | Rhodamine B | 10–200 | C57BL/6J mice | (Wang et al., 2021) |